Month: March 2026

Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Written by Customer Service on March 25, 2026. Posted in Public Companies.

– FDA Grants IND Clearance for SER-252– SER-252 Phase 1b Trial Initiated– Closed Private Placement Financing of up to $30 Million HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the full year ended December 31, 2025 and provided recent business highlights. “This past year was defined by execution, advancing SER-252 from IND filing through FDA clearance, into the clinic while strengthening our balance sheet to support the clinical milestones ahead,” said Steve Ledger, CEO of Serina. “With the first patient dosed in our registrational trial in advanced Parkinson’s...

Exicure, Inc. Reports Full Year 2025 Financial Results

Written by Customer Service on March 25, 2026. Posted in Earnings Releases And Operating Results.

REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) — Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position: Cash and cash equivalents were $3.7 million as of December 31, 2025, compared to $12.5 million as of December 31, 2024. Our current liquidity may not be sufficient to fund operations for the next 12 months. Additional financing will be required to support ongoing operations, continue the exploration of strategic alternatives, and pursue any alternatives that we identify. Research and Development (R&D) Expense: Research and development expenses were $3.3 million for the year ended December 31, 2025, as compared to $0 for the year ended December 31, 2024. The increase of $3.3 million reflects R&D activities...

Exicure, Inc. Reports Full Year 2025 Financial Results

Written by Customer Service on March 25, 2026. Posted in Earnings Releases And Operating Results.

Caliber Reports Fourth Quarter and Full Year 2025 Results

Written by Customer Service on March 25, 2026. Posted in Earnings Releases And Operating Results.

Establishes 2026 Guidance: Revenue Range of $18 Million to $22 Million with Positive Net Operating Income and Adjusted EBITDA Profitability SCOTTSDALE, Ariz., March 25, 2026 (GLOBE NEWSWIRE) — Caliber (Nasdaq: CWD), a diversified real estate and digital asset management platform, today reported results for the fourth quarter and full year ended December 31, 2025. Caliber enters 2026 with a streamlined platform and a clear path toward revenue growth and profitability, driven by the expected execution of project-level financings and continued capital formation activities. Fourth Quarter 2025 (compared to Fourth Quarter 2024)Platform revenue of $4.0 million, compared to $4.6 millionAsset management revenue of $4.0 million drove the stated resultsPlatform net loss of $7.7 million, or $1.24 per diluted share, compared to Platform...

Omega Flex, Inc. Announces Regular Quarterly Dividend for the First Quarter 2026

Written by Customer Service on March 25, 2026. Posted in Dividend Reports And Estimates.

EXTON, Pa., March 25, 2026 (GLOBE NEWSWIRE) — Omega Flex, Inc. (the “Company”) (NASDAQ: OFLX) today announced that the Board of Directors declared a regular quarterly dividend of $0.34 per share payable on April 21, 2026, to shareholders of record on April 9, 2026. In determining the amount of future regular quarterly dividends, the Board will review the cash needs of the Company, and based on results of operations, financial condition, capital expenditure plans, and consideration of possible acquisitions, as well as such other factors as the Board of Directors may consider relevant, determine on a quarterly basis the amount of a regular quarterly dividend. INFORMATION CONCERNING FORWARD-LOOKING STATEMENTS – This press release contains forward-looking statements, which are subject to inherent uncertainties which are difficult...

ARMOUR Residential REIT, Inc. Announces Guidance for April 2026 Dividend Rate per Common Share

Written by Customer Service on March 25, 2026. Posted in Dividend Reports And Estimates.

VERO BEACH, Florida, March 25, 2026 (GLOBE NEWSWIRE) — ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) (“ARMOUR” or the “Company”) today announced guidance on the April 2026 cash dividend for the Company’s Common Stock of $0.24 per Common share. April 2026 Common Stock Dividend InformationMonth Dividend Holder of Record Date Payment DateApril 2026 $0.24 April 15, 2026 April 29, 2026Certain Tax Matters ARMOUR has elected to be taxed as a real estate investment trust (“REIT”) for U.S. Federal income tax purposes. In order to maintain this tax status, ARMOUR is required to timely distribute substantially all of its ordinary REIT taxable income. Dividends paid in excess of current tax earnings and profits for the year will generally not be taxable to common stockholders. Actual dividends are determined...

Orezone Gold Reports Fourth Quarter 2025 Results and Provides 2026 Guidance

Written by Customer Service on March 25, 2026. Posted in Earnings Releases And Operating Results.

All dollar amounts are in USD unless otherwise indicated and abbreviation “M” means million. VANCOUVER, British Columbia, March 25, 2026 (GLOBE NEWSWIRE) — Orezone Gold Corporation (TSX: ORE | ASX: ORE | OTCQX: ORZCF) (“Orezone” or “Company”) is pleased to report its operational and financial results for the fourth quarter and year ended December 31, 2025, and its 2026 guidance. The Company will host a conference call and webcast today at 2:00pm PT / 5:00pm ET to discuss the results. Details to join the conference call and webcast are provided at the end of this release. Fourth Quarter 2025 HighlightsGold production of 30,407 oz at an AISC of $1,942 per ounce sold. Revenue of $130.5M from the sale of 31,526 oz at an average realized price of $4,129 per oz. Adjusted EBITDA of $63.0M, Adjusted Earnings attributable to Orezone shareholders...

Orezone Gold Completes Strategic Acquisition of Casa Berardi Gold Mine and Quebec Exploration Portfolio

Written by Customer Service on March 25, 2026. Posted in Mergers And Acquisitions.

All dollar amounts are in USD unless otherwise indicated and abbreviation “M” means million.Strategic acquisition of an established operating gold mine, located in a Tier 1 mining jurisdiction Positions Orezone as a diversified multi-asset producer, adding material scale, production and free cash flow Acquisition builds on Orezone’s strong track record of operating and development success, providing an excellent platform for future growth and value creationVANCOUVER, British Columbia, March 25, 2026 (GLOBE NEWSWIRE) — Orezone Gold Corporation (TSX: ORE | ASX: ORE | OTCQX: ORZCF) (“Orezone” or “Company”) is pleased to announce that the Company has completed its acquisition (the “Transaction”) of Hecla Quebec Inc. (“Hecla Quebec”), a wholly owned subsidiary of Hecla Mining Company (“Hecla Mining”). Through this Transaction, Orezone...

Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights

Written by Customer Service on March 25, 2026. Posted in Earnings Releases And Operating Results.

Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafter Cash and cash equivalents, inclusive of the March 2026 financing, expected to fund operations into 2029 LA JOLLA, Calif, March 25, 2026 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for its fourth quarter and fiscal year ended December 31, 2025. “2025 was a transformative year as we sharpened our strategic focus on EQ504 and strengthened our financial position to support its advancement into the clinic,” said Bruce Steel, Chief Executive Officer of Equillium. “Our financing in August 2025 of...

SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Written by Customer Service on March 25, 2026. Posted in Earnings Releases And Operating Results.

Added top-rated children’s hospitals to QUELIMMUNE™ pediatric Acute Kidney Injury (AKI) customer base Completed enrollment in FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry Exceeded 50% enrollment milestone in pivotal trial of SCD therapy in adult patients with AKI Advanced pipeline indications with initiation of cardio-renal clinical trial Webcast today at 4:30 pm Eastern Time DENVER, March 25, 2026 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months and year ended December 31, 2025, and provided business updates on key initiatives. “In 2025, we broadened our customer base of top-ranked children’s...

Month: March 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals